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Introduction 
Hirschsprung’s disease (HSCR) or aganglionic 
megacolon is characterized by the absence of 
parasymphathetic intrinsic ganglion cells in the 
submucosal and myentric plexuses in the 
gastrointestinal tract [1-3]. The disease can be sub-
divided into 3 groups including short-segment (S-
HSCR, aganglionosis up to upper sigmoid colon), 
long-segment (L-HSCR, aganglionosis up to the 
splenic flexure and beyond) and total colonic 
aganglionosis (TCA) [4]. HSCR presents in the 
neonatal period or in early childhood with symptoms 
ranging from chronic constipation to acute ileus. 
However, late manifestation in adults has also been 
described [5].  HSCR is the most common cause of 
neonatal intestinal obstruction and it affects one in 
5,000 newborns with a male predominance of 3:1 to 
5:1 [6-7]. 
 
HSCR is likely to be of multifactorial inheritance and 
associated with genes involved in the signaling 
pathway of enteric nervous system (ENS) including 
the RET (REarranged during Transfection), glial 
derived neurotrophic factor (GDNF), endothelin 
receptor B (EDNRB) genes and endothelin 3 (EDN3) 
[5, 8].  These genes are interrelated and involved in the 
development of enteric ganglia from the specific 
lineage of neutral crest cells [5, 8].  RET encodes for a 
receptor tyrosine kinase and is a major susceptibility 
gene for HSCR [9-11]. This gene is located in the 
10q11.2 which transcribes for a transmembrane 
receptor with a cadherin-like extracellular domain, a 
cysteine-rich region and an intracellular tyrosine 
kinase domain [12]. Heterozygous variants in the RET 
gene accounts for 7-35% of sporadic HSCR and 
around 50% of familial HSCR cases [8]. Variants 
reported include missense, nonsense, deletion, 
insertion and frameshift mutations and are present 
throughout the whole RET gene sequences [13-17]. 
Some studies have also shown that certain variants of 
the RET gene serves as low susceptibility factors and 
modify the penetrance and severity of the HSCR 
phenotype [18].   
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Abstract 
 
Hirschsprung’s disease (HSCR) is a disorder associated with congenital absence of ganglion cells in the 
gastrointestinal tract.  Molecular analyses have identified variants in various genes including RET, GDNF, 
EDN3 and EDNRB that are involved in the development, migration and survival of neural cells. Variants 
in the receptor tyrosine kinase (RET) are most common and have been identified in 10-20% of sporadic 
HSCR patients. The objective of this study was to screen for RET gene variants in Malaysian patients with 
HSCR. Thirty-two patients with HSCR and 30 normal controls were recruited for this study. Mutations 
were screened using the Polymerase Chain Reaction – Denaturing High Performance Liquid 
Chromatography (PCR-dHPLC) approach. Mutations identified were then confirmed using Sanger 
sequencing. We identified one novel rare variant in exon 4 (A268A c807 G>C) in one patient. We also 
identified the common coding sequence variantsA45A (c135G>A), A432A (c1296A>G), L769L (c2307 T>G) 
and the G691S in our cohort of patients.  In conclusion, our Malaysian patients with HSCR diseases showed 
the presence of similar RET gene common variants which have been described in other populations. We 
have also identified a novel variant in exon 4 (A268A). 
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There is a significant racial variation in the incidence 
of the disease worldwide, with the highest prevalence 
among Asians [9, 15, 19-22]. Eight heterozygous rare 
variants (RVs) were detected in 13 Vietnamese 
patients (13.40%) in which the variants were not 
present in healthy individuals [17]. Among those 
variants, 2 were novel and deleterious (R133C [c.397 
C>T]; R144C [c.430 C>T]) and 4 have been described 
previously (R114H [c.341 G>A]; V292M [c.874 
G>A]; G533S [c.1597 G>A]; R982C [c.2944 C>T]) 
(17). The common RET coding sequence variants are 
rs1800858 (A45A [c.135 G>A]) and rs1800861 
(L769L [c.2307 T>G]) and were highly associated 
with the disease [17]. Other common variants 
associated with HSCR that have been reported 
previously in Taiwan were c135G>A (rs1800858, 
A45A) in exon 2, c1296A>G (rs1800860, A432A) in 
exon 7, c2307T>G (rs1800861, L769L) in exon 13 and 
c2712C>G (rs1800863, S904S) in exon 15 [8].  A 
recent study in southern Thailand showed similar 
sequence variants for RET gene [22]. They identified 
additional novel rare variants in exon 2, 4 and 8 which 
were c299G>T (S100M), c692G>A (R231H), 
c833C>A (T278N) and c1597G>A (G533S) [22].  
About 11 different nucleotide substitutions were 
identified in Korean patients with HSCR [15]. Of 
these, 2 were new missense mutations (C558Y and 
R844W) and 9 were previously described variants 
[15]. Although the common and rare variants of RET 
have been extensively characterized in HSCR patients 
from various ethnic groups, the genotype data from 
Malaysia has yet to be investigated.  Therefore, this 
 
  
study was performed to determine the variation in the 
RET gene of Malaysian HSCR patients.   
 
Materials and methods 
 
Patient collection and DNA samples 
 
A total of 32 HSCR patients and 30 normal controls 
(healthy unselected and unrelated individuals) were 
recruited into this study. Of the 32 HSCR patients 
included in the study, 26 were Malays, 5 were Chinese 
and 1 was Indian. Twenty-five patients were male and 
7 patients were female. The mean age of the patients 
was 2.98 years (1 month – 11 years). Controls were 
collected from patients who came to the hospital for 
diagnosis other than HSCR. Of the 30 non-HSCR 
controls, 20 were Malays, 8 were Chinese and 2 were 
Indians. There were fifteen male and 15 female 
controls. The mean age of the normal controls was 
7.83 years (3 – 11 years). Written informed consent 
was obtained from the parents of all patients and the 
study was approved by the UKM Medical Centre 
(UKMMC) Ethics Committee. About 3ml of 
peripheral blood was drawn from the subjects into the 
EDTA blood container for DNA isolation using the 
conventional ‘salting out’ method with slight 
modification [23].  The clinical details of the 32 HSCR 
patients are given in Table 1. Mean age for HSCR 
group are younger than the control group, due to the 
early presentation of the disease in a patient’s life. 
Majority of the patients (81.25%) were diagnosed as 
with aganglionosis to the recto-sigmoid HSCR. 
 
 
 
Polymerase chain reaction (PCR) 
 
PCR amplification of 20 exons of the RET gene was 
performed as previously described with slight 
modification [24-26]. HotStar Taq polymerase was 
used for PCR amplification. The PCR reactions and 
conditions differed depending on the size of the PCR 
products. The PCR reactions consisted of 0.4 - 25 M 
of forward and reverse primers, 2.0 - 2.5U of HotStar  
Taq DNA polymerase, 50 - 250 ng of template DNA, 
1.5 - 3.0 mM of MgCl2, 0.16 - 0.4 mM of dNTP’s and 
1x of PCR buffer. The PCR conditions were as 
follows: initial denaturation at 95°C for 4 min, 35 
cycles of denaturation step at 95°C for 4 min, 
annealing temperature from 50 - 60°C, extension at 
72°C for 45 seconds and followed by final extension 
at 72°C for 1 minute. 
 
Table 1. Clinical data of 32 patients with Hirschsprung’s disease.
Description HSCR (n=32) Controls (n=30)
Demographic data 
a) Mean age + SD (years) 2.98 + 3.2 7.83+2.520 : 8 : 2
b) Ethnic ratio (Malay:Chinese:Indian) 26 : 5 : 1 15 : 15
c) Gender (Male, female) 26 : 6
Clinical Data
a)   Total colonic aganglionosis (TCA) 4/32 = 12.5% no related
b)   Recto-sigmoid 26/32 = 81.25% not related
c)   Up to proximal end of sigmoid 2/32 = 6.25% not related
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Denaturing high performance liquid chromatography 
(dHPLC) 
 
Analysis by dHPLC was carried out using the 
HelixTM Varian System (Varian Analytical 
Instrument, Palo Alto, CA, USA). Approximately 10 
to 20 µl of the PCR products (50 - 100 ng of DNA) 
were denatured for 3 minutes at 95°C, and gradually 
reannealed at decreasing temperature from 95°C to 
65°C for 30 minutes to form the heteroduplexes 
molecules. The PCR products were separated at 0.9 
ml/min linear acetonitrile gradient. The column 
mobile phase consisted of 0.1 M triethylamine acetate 
(pH 7.0) with Buffer B. 
 
DNA sequence analysis 
 
DNA sequencing was performed using the ABI 3100 
Genetic Analyzer (Applied Biosystem, New York, 
USA). The PCR products were purified using a 
commercially available kit (Qiagen, Germany). The 
sequencing reactions were performed using the 
BigDye Terminator Kit V3.1 (Applied Biosystem, 
USA). The cycle sequencing reactions were as 
follows: 50 - 100 nmol of purified PCR products, 2 µl 
of BigDye Terminator Kit V3.1, 1 µl of Sequencing 
Buffer, 3.2 pmoles of primer in a total volume of 20 
µl. Cycle sequencing was performed using 55 cycles 
and consisted of 96°C at 5 minutes, 60°C at 5 minutes 
and 96°C at 5 minutes. The cycle sequencing products 
were then purified using ethanol/sodium acetate 
precipitation. Finally, the products were sequenced 
using the standard method from Applied Biosystem,  
 
 
 
USA. DNA sequencing was performed only in exon 2,  
4, 7, 11 and 13 for control subjects as only these exons 
showed SNPs.  DNA sequencing results were 
analyzed using Basic Local Alignment System Tools 
(BLAST).Reference sequences and SNP information 
of the RET gene were obtained from the Ensemble  
Human Genome Browser 
(http://www.ensemble.org/Homo_sapiens) and the 
National Center for Biotechnology Information, NCBI 
(http://www.ncbi.nih.gov). 
 
Prediction of mutation pathogenicity 
 
The Piezoelectric Micro Machine Ultrasonic 
Transducers (PMut) software which uses the neural 
network (NN) algorithm was applied to predict the 
pathogenicity of each variant 
(http://mmb2.pcb.ub.es:8080/PMut) [17]. The neural 
network (NN) predicts the outcome of a particular 
variant using different types of sequence information 
to label the variants and subsequently process the 
information.  A variant is predicted to be pathogenic 
when the NN output is >0.5 [17].  
 
Statistical analysis 
 
Fisher’s Exact and 2 tests were used to determine the 
significance of the association of the allele frequencies 
between patients and normal control groups. Our 
calculation was based on the R programming 
language. A p value of < 0.05 was considered as 
statistically significant. 
  
 
Table 2. Allelic distribution frequency of the RET  gene variants.
c135 A:96% 31 0.86 A:77% 23 0.52
G>A: A45A G:4% 1 0.14 G:23% 7 0.48
NA
G>C: A268A G:97% 31 0.98
1
A>G: A432A A:4% 1 0.13 A:0% 0 0.85
0.04962
G>A: G691S
(rs1799939)
0.02411
T>G: L769L T:4% 1 0.16 T:23% 7 0.48
32 30
9.14
Total
P-value
13
c2307 G:96% 31 0.84 G:77% 23 0.52  1.05 - 
437.5
0.13
G:97% 31 0.98 G:80% 24 0.88
0
11
c2073 A:3% 1 0.02 A:20% 6 0.12
 0 - 1.2
NA
7
c1296 G:96% 31 0.88 G:100% 30 0.15
0 -  41.6
0.02411
4
c807 C:3% 1 0.02
NA NA NA NA
# of 
individuals
Allele 
frequencies
95% CI OR
2
 1.0 -  
437.5
9.14
Exon
Nucleotide 
change
HSCR (%)
# of 
individuals
Allele 
frequencies
Control (%)
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Results 
 
We analyzed the whole exonic region of the RET gene 
in this cohort of patients. We identified 4 common 
variants and 1 novel variant (Table II). The common 
variants include A45A, A432A and L769L in exons 2, 
7, and 13 respectively. Another variant involved the 
substitution of nucleotide G>A in exon 11, resulting in 
the G691S variant. The G691S variant has been 
predicted to be benign with a score of 0.103 
(sensitivity: 0.93; specificity: 0.86) using PolyPhen 2 
web-based tool [9]. We also identified a novel variant 
in one patient. This is the A268A (c807G>C) variant 
in exon 4. Table III shows the frequency of the variants 
in HSCR patients from different populations.  
 
Discussion 
 
In total, we identified 4 common variants and 1 novel 
variant in the RET gene from our HSCR patients. The 
A45A (G>A) variant in exon 2 was identified in 97% 
of our patients and in 77% of the normal controls. 
Almost all patients with A45A are those with short 
segment agangliosis (SSA). This silent A45A variant 
has been reported in HSCR patients of different ethnic 
background including German and Chinese [11, 30]. 
Wu and colleagues suggested that the presence of 
A45A and L769L polymorphisms were significantly 
higher in patients with LSA compared to SSA [8]. 
Fitze and colleagues has reported the association 
between the c135G/A genotype and RET germline 
mutations with the phenotype of HSCR. [31].  
 
Our results are generally in agreement with other 
studies. In Taiwan, the A45A, A432A, G691S and 
L769L variants were identified in both patients and 
controls [8, 18]. The A45A was identified in 68% of 
HSCR and 54% of controls while the L769L variant  
 
 
was found in 72% of HSCR and 53% of controls [18]. 
Our study showed that the A45A and L769L variants 
were present at a higher frequency in Malaysian 
HSCR patients compared to patients from Germany 
and China although our sample size is smaller (Table 
3).  
 
Only 1 (3%) of our HSCR patients showed the 
presence of the G691S variant. This frequency is much 
lower than the other populations and possibly due to 
the fact that our patients were mostly sporadic cases. 
Fitze and colleagues suggested that the mutation in 
exon 11, may possibly result in complete or partial loss 
of RET kinase activity [31]. Borrello and colleagues 
proposed a modifier role for the RET G691S where 
together with K666E, it enhances the transforming 
activity which results in increased downstream 
signaling of the RET gene [30]. The c807G>C 
(A268A) is a novel variant which was detected in a 
Malay patient. Given that this variant was not detected 
in the control group, the association of this variant with 
HSCR requires further evaluation in a bigger set of 
patients. 
 
Advances in sequencing technologies have made 
mutational screening more robust where exome or 
targeted sequencing may be used to characterize 
mutations in several genes simultaneously. Current 
higher throughput sequencing platforms would 
potentially yield more information compared to the 
dHPLC and DNA sequencing techniques we used for 
this study.  
 
In conclusion, we have identified 5 variants, including 
the novel A268A variant. The DHPLC-DNA 
sequencing proves to be a feasible approach to detect 
mutations and polymorphisms in patients with HSCR. 
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